TECFIDERA Drug Patent Profile

When do Tecfidera patents expire, and when can generic versions of Tecfidera launch?

Tecfidera is a drug marketed by Biogen Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-nine countries.

The generic ingredient in TECFIDERA is dimethyl fumarate. There are seventy-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the dimethyl fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tecfidera

A generic version of TECFIDERA was approved as dimethyl fumarate by MYLAN on August 17^th, 2020.

Summary for TECFIDERA

International Patents:	94
US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TECFIDERA

Paragraph IV (Patent) Challenges for TECFIDERA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TECFIDERA	Delayed-release Capsules	dimethyl fumarate	120 mg and 240 mg	204063	29	2017-03-27

US Patents and Regulatory Information for TECFIDERA

TECFIDERA is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	AB	RX	Yes	No
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013	AB	RX	Yes	Yes
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	AB	RX	Yes	No
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	AB	RX	Yes	No

International Patents for TECFIDERA

See the table below for patents covering TECFIDERA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20210111362	다발성 경화증을 치료하는 방법 (METHODS OF TREATING MULTIPLE SCLEROSIS)
Poland	2653873
Spain	2195664
European Patent Office	1131065	DIALKYLFUMARATES POUR LE TRAITEMENT DE MALADIES AUTOIMMUNES (DIALKYLFUMARATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES)

Supplementary Protection Certificates for TECFIDERA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1131065	39/2014	Austria		PRODUCT NAME: DIMETHYLFUMARAT; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
2137537	SPC/GB14/046	United Kingdom		PRODUCT NAME: DIMETHYL FUMARATE; REGISTERED: UK EU/1/13/837 20140203
0605697	SPC/GB01/008	United Kingdom		PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026
2653873	LUC00294	Luxembourg		PRODUCT NAME: DIMETHYL FUMARATE (TECFIDERA); AUTHORISATION NUMBER AND DATE: EU/1/13/837/001-002 20140203

TECFIDERA: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

TECFIDERA (dimethyl fumarate) is a leading oral disease-modifying therapy (DMT) approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Since its launch in 2013, TECFIDERA has become a significant revenue driver for Biogen, consolidating its position amid competitive pressure from other MS therapies. This report provides an in-depth analysis of the current investment landscape, market dynamics, and financial projections for TECFIDERA, considering recent patent statuses, market competition, regulatory factors, and possible future growth pathways.

---

1. Market Overview and Historical Development

1.1. TECFIDERA’s Market Position

Parameter	Details	Source
Approval Date	August 2013	[1]
Indications	RRMS	[1]
Annual Global Sales (2022)	$3.1 billion	[2]
Market Share (MS DMTs, 2022)	~14%	[3]

TECFIDERA has maintained a leading position among oral DMTs, competing substantially with other oral therapies such as Aubagio (teriflunomide) and Gilenya (fingolimod). The drug's favorable safety profile and efficacy contributed to rapid uptake post-approval.

1.2. Patents and Exclusivity

Patent/Protection	Expiry / Status	Implication
Composition of Matter Patent	2028 (U.S.)	Patent exclusivity for key molecule
Data Exclusivity	Until 2023-2024 (varies by region)	Market exclusivity for data
Patent Challenges/Disputes	Ongoing	Potential impact on future revenues

Patent expirations targeted around 2028 are pivotal for market competition. The patent status influences both current valuation and future investment decisions.

---

2. Market Dynamics Influencing TECFIDERA

2.1. Competitive Landscape

Competitor	Mechanism	Market Share (2022)	Key Differentiator
Aubagio (teriflunomide)	Oral DMT	~13%	Slightly different safety profile
Gilenya (fingolimod)	Oral DMT	~15%	Higher efficacy but higher risk profile
Mavenclad (cladribine)	Oral DMT	Emerging	Short-course pulsatile therapy

In 2022, TECFIDERA's market share plateaued, faced stiff competition from newer oral agents, and innovations that appeal to complex patient profiles.

2.2. Pricing and Reimbursement Trends

Region	Average Wholesale Price (AWP)	Reimbursement Rate	Notes
U.S.	~$65,000/year	High, but with co-pays	Insurers increasingly scrutinize costs
Europe	Varies by country	Typically reimbursed	Regulatory price controls dominate

Pricing pressures, especially in Europe and the U.S., influence revenue trajectories. Payer negotiations and formulary placements are increasingly critical.

2.3. Regulatory and Patent Litigation

Patent disputes threaten potential generic entry, especially post-2028. Multiple jurisdictions face patent litigations which could extend exclusivity or open paths for biosimilars.

2.4. Patient and Prescriber Trends

Shift towards oral therapies has increased overall market size but intensified competition. Patient preference for safety and convenience strongly influences prescribing behavior.

---

3. Financial Trajectory and Investment Outlook

3.1. Revenue Projections (2023-2030)

Year	Estimated Sales (USD billions)	Assumptions
2023	$3.2	Slight growth, patent expiry looming
2024	$3.1	Patent cliff begins to impact sales
2025	$2.8	Entry of generics leads to volume decline
2026	$2.4	Greater generic penetration, market share loss
2027	$2.0	Potential major generic infringement
2028	$1.5	Patent expiry, significant generic entrants
2029	$1.0	Extended generic competition
2030	$0.8	Market stabilizes at lower levels

Key drivers: Patent expiry in 2028, price erosion, generics, and biosimilar/substitute developments.

3.2. Investment Risks and Opportunities

Risk Factors	Impact	Mitigation Strategies
Patent expiration	Sharp revenue decline	Diversification into new indications or formulations
Competition from novel DMTs	Market share erosion	Lifecycle management, combination therapies
Regulatory delays	Post-market challenges	Early engagement with authorities

Opportunity Areas	Growth Potential	Strategic Considerations
Line extension (e.g., deviations, formulations)	Moderate	R&D investment
New indications	High	Clinical development pipelines
Market expansion (e.g., emerging markets)	High	Local partnerships

---

4. Strategic Considerations for Investors

4.1. Pre-Patent Expiry Phase (Until 2028)

• Stability in revenue streams due to patent protection
• Potential for maximized profitability, especially through pricing strategies and managed care negotiations
• Limited growth outside of market share expansion or formulation improvements

4.2. Post-Patent Expiry Phase (2028 onward)

• Anticipate revenue decline by 40-50% over five years
• Elevated generic competition risk necessitates cost management and pipeline expansion
• Explore biosimilar and specialty formulations for new revenue opportunities

4.3. Mergers, Acquisitions, and Collaborations

Increased consolidation in the pharmaceutical sector, with companies investing in proprietary drug delivery platforms, biosimilars, and combination therapies, may influence TECFIDERA’s long-term value.

---

5. Comparative Analysis with Market Peers

Parameter	TECFIDERA	Gilenya	Aubagio	Mavenclad
FDA Approval	2013	2010	2013	2019
Mode of Action	ER/NR	S1P modulator	DHODH inhibitor	Cladribine (pulsed)
Estimated 2022 Revenue	$3.1 B	$2.7 B	$1.8 B	$0.3 B
Patent Status	Valid until 2028	Expired	Valid until 2027	New entrant, patent pending

The competitive landscape suggests TECFIDERA remains influential pre-patent expiration but faces inevitable decline thereafter.

---

6. Policy and Regulatory Environment Impact

• Pricing controls: Increasing in European markets
• Patent law changes: Potential for extendable exclusivity through patent extensions
• Healthcare reforms: Potential for formulary restrictions impacting sales volume

---

7. Future Outlook and Growth Strategies

• Strengthening proprietary formulations and delivery methods
• Expanding indications to other neurodegenerative or autoimmune diseases
• Investing in digital health and adherence support tools to reduce discontinuation
• Developing biosimilars and generics for market penetration post-patent expiry

---

8. Key Takeaways

• TECFIDERA’s revenue will likely peak pre-2028, with significant decline forecasted post-patent expiry.
• The competitive environment is evolving rapidly, with newer therapies gaining market share.
• Market dynamics favor diversification: pipeline expansion, formulation innovation, and geographic growth are critical.
• Regulatory and patent strategies will significantly influence timelines and revenue projections.
• Investors should balance aging revenue streams with innovative pipeline investments and strategic partnerships.

---

9. Frequently Asked Questions (FAQs)

Q1: When will TECFIDERA patents expire, and what does it mean for investors?

A: The primary composition of matter patent in the U.S. expires around 2028. Post-expiry, generic manufacturers can enter the market, leading to significant revenue erosion for TECFIDERA. Investors should consider the implications of patent cliffs and potential generic competition.

Q2: How does TECFIDERA compare to newer or alternative MS therapies?

A: TECFIDERA remains a top oral therapy, particularly valued for its safety profile. Newer agents like Mavenclad or BIF in development offer alternative mechanisms, many with benefits in efficacy or dosing but also with distinct risk profiles.

Q3: What are the primary risks affecting TECFIDERA’s financial outlook?

A: Patent expiration, increased competition, pricing pressures, regulatory challenges, and macroeconomic factors impacting healthcare budgets are key risks.

Q4: Are there opportunities for TECFIDERA’s growth in emerging markets?

A: Yes, emerging markets represent significant growth potential due to increasing MS diagnosis rates and expanding healthcare infrastructure, though economic and regulatory barriers exist.

Q5: What strategic moves can prolong TECFIDERA’s market relevance?

A: Lifecycle management through new formulations, investigating additional indications, collaborations, and expanding into biosimilars or combination therapies can extend relevancy beyond patent expiry.

---

References

[1] FDA. (2013). TECFIDERA Approval Letter.
[2] Evaluate Pharma. (2022). World Preview Market Data.
[3] IQVIA. (2022). MS Market Share Report.